Kinetic characterization of recombinant human glutathione transferase T1-1, a polymorphic detoxication enzyme
Typical Clinical Ranges Loading Phase: 25 mg per week (subcutaneous injection) for 46 weeks Maintenance Phase: 2 mg every 12 weeks after the loading period Key Considerations Personalization: Dosage should be adjusted based on individual symptoms, sensitivities, and treatment response
As oxidative stress decreases, patients may also experience improved vitality and overall wellness
| 2025 | Curr Rev Musculoskelet Med 3 4Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration | Wilton et al
In severe cases, this may be accompanied by sweating, shortness of breath, chest pain, hoarseness, facial swelling, and fever